drugset / Trial / NCT07576868
A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled Phase 2/3 study to evaluate the efficacy, safety, and antiviral activity of CP-COV03 in adult patients with dengue infection.
Timeline
- Start
- 2026-04-09
- Primary completion
- 2027-01
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CP-COV03 | Unknown | 450 mg | Oral |
| Subject | CP-COV03 | Unknown | 900 mg | Oral |
| Subject | CP-COV03 | Unknown | 1350 mg | Oral |